JAKARTA – PT Prodia Widyahusada Tbk (PRDA), the operator of Prodia diagnostic laboratory network, recorded only a slight increase in both revenue and profit, growing by 1.3% and 4% year-on-year (yoy) respectively in 2024.

According to the 2024 Financial Report, PRDA’s revenue rose from IDR 2.22 trillion to IDR 2.25 trillion.

“The largest revenue contribution came from the B2C customer segment, accounting for 58% of total revenue,” management stated in an official release today (14/3).

The B2C segment contributed IDR 680.47 billion, followed by revenue from doctor referrals and third parties at IDR 616.65 billion and IDR 600.14 billion respectively. Corporate clients slightly lagged behind, contributing IDR 354.93 billion.

In terms of test types, demand for routine tests dominated revenue portions in 2024. “The largest revenue contribution came from routine tests, amounting to IDR 1.57 trillion, contributing 69% to the Company’s total revenue,” management added.

On the bottom line, net profit showed moderate growth, increasing by 4% yoy to IDR 270.20 billion in 2024.

Responding to this, PRDA's President Director, Dewi Muliaty, outlined plans to enhance performance in 2025, focusing on expanding the esoteric testing segment.

“In 2025, we aim to introduce 14 new tests annually,” Dewi added. As of December 2024, the esoteric testing segment contributed IDR 492.39 billion, representing 21.86% of total revenue.

Additionally, PRDA will also optimise its customer service network, both B2C and B2B, and expand its reach as a Southeast Asia Referral Laboratory (SEA Referral Laboratory). (ZH)